Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?
Authors:
Preprint
- 14 August 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Plasma pharmacokinetic (PK) profiles often do not resemble the PK within the central nervous system (CNS) because of blood-brain-border (BBB) processes, like active efflux by P-glycoprotein (P-gp). Methods to predict CNS-PK are therefore desired. Here we investigate whether in vitro apparent permeability (Papp) and corrected efflux ratio (ERc) extracted from literature can be repurposed as input for the LeiCNS-PK3.4 physiologically-based PK model to confidently predict rat brain extracellular fluid (ECF) PK of P-gp substrates. Literature values of in vitro Caco-2, LLC-PK1-mdr1a/MDR1, and MDCKII-MDR1 cell line transport data were used to calculate P-gp efflux clearance (CLPgp). Subsequently, CLPgp was scaled from in vitro to in vivo through a relative expression factor (REF) based on P-gp expression differences. BrainECF PK was predicted well (within 2-fold error of the observed data) for 2 out of 4 P-gp substrates after short infusions and 3 out of 4 P-gp substrates after continuous infusions. Prediction accuracy was influenced by variability in reported ERc and in vitro P-gp expression. Notably, use of Papp and in vitro P-gp expression obtained from a single study did not guarantee an accurate prediction; it often resulted in worse predictions than when using in vitro expression values reported by other labs. Using Papp and P-gp expression as input, LeiCNS-PK3.4 shows promise in predicting brainECF PK but this study highlights that the in vitro to in vivo translation is not yet robust. We conclude that more information is needed about context and drug dependency of in vitro data for robust brainECF PK predictions.Keywords
All Related Versions
This publication has 96 references indexed in Scilit:
- Evaluation of bottom‐up modeling of the blood–brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modelingBiopharmaceutics & Drug Disposition, 2023
- Successful Prediction of Human Steady‐State Unbound Brain‐to‐Plasma Concentration Ratio of P‐gp Substrates Using the Proteomics‐Informed Relative Expression Factor ApproachClinical Pharmacology & Therapeutics, 2021
- Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer TreatmentClinical Pharmacology & Therapeutics, 2020
- Translational aspects of blood–brain barrier transport and central nervous system effects of drugs: From discovery to patientsClinical Pharmacology & Therapeutics, 2015
- Development of a Physiologically Based Pharmacokinetic Model for the Rat Central Nervous System and Determination of an In Vitro–In Vivo Scaling Methodology for the Blood–Brain Barrier Permeability of Two Transporter Substrates, Morphine and OxycodoneJournal of Pharmaceutical Sciences, 2012
- Development of a new permeability assay using low‐efflux MDCKII cellsJournal of Pharmaceutical Sciences, 2011
- P‐glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during agingCytometry Part A, 2011
- Variability in Caco-2 and MDCK Cell-Based Intestinal Permeability AssaysJournal of Pharmaceutical Sciences, 2008
- Effect of P‐Glycoprotein Expression Levels on the Concentration‐Dependent Permeability of Drugs to the Cell MembraneJournal of Pharmaceutical Sciences, 2008
- Morphology of the differentiation and maturation of LLC‐PK1 epitheliaJournal of Cellular Physiology, 1990